HK1055059A2 - 5-SUBSTITUTED 7,9-DIFLUORO-5H-CHROMENO[3,4-f]QUINOLINE COMPOUNDS AS SELECTIVE PROGESTERONE RECEPTOR MODULATOR COMPOUNDS - Google Patents

5-SUBSTITUTED 7,9-DIFLUORO-5H-CHROMENO[3,4-f]QUINOLINE COMPOUNDS AS SELECTIVE PROGESTERONE RECEPTOR MODULATOR COMPOUNDS Download PDF

Info

Publication number
HK1055059A2
HK1055059A2 HK03105598A HK03105598A HK1055059A2 HK 1055059 A2 HK1055059 A2 HK 1055059A2 HK 03105598 A HK03105598 A HK 03105598A HK 03105598 A HK03105598 A HK 03105598A HK 1055059 A2 HK1055059 A2 HK 1055059A2
Authority
HK
Hong Kong
Prior art keywords
compounds
chromeno
difluoro
substituted
progesterone receptor
Prior art date
Application number
HK03105598A
Other languages
English (en)
Chinese (zh)
Inventor
Zhi Lin
Arjan Van Oeveren Cornelis
Pedram Bijan
Karanewsky Donald
Original Assignee
Ligand Pharmaceuticals Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ligand Pharmaceuticals Incorporated filed Critical Ligand Pharmaceuticals Incorporated
Publication of HK1055059A2 publication Critical patent/HK1055059A2/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HK03105598A 2002-10-11 2003-08-04 5-SUBSTITUTED 7,9-DIFLUORO-5H-CHROMENO[3,4-f]QUINOLINE COMPOUNDS AS SELECTIVE PROGESTERONE RECEPTOR MODULATOR COMPOUNDS HK1055059A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41796802P 2002-10-11 2002-10-11
US60/417,968 2002-10-11

Publications (1)

Publication Number Publication Date
HK1055059A2 true HK1055059A2 (en) 2003-12-05

Family

ID=31994318

Family Applications (1)

Application Number Title Priority Date Filing Date
HK03105598A HK1055059A2 (en) 2002-10-11 2003-08-04 5-SUBSTITUTED 7,9-DIFLUORO-5H-CHROMENO[3,4-f]QUINOLINE COMPOUNDS AS SELECTIVE PROGESTERONE RECEPTOR MODULATOR COMPOUNDS

Country Status (12)

Country Link
US (1) US7163946B2 (OSRAM)
EP (1) EP1554283A1 (OSRAM)
JP (1) JP2006504737A (OSRAM)
AR (1) AR040781A1 (OSRAM)
AU (1) AU2003258051A1 (OSRAM)
CA (1) CA2501834A1 (OSRAM)
CL (1) CL2003001545A1 (OSRAM)
DE (1) DE20301728U1 (OSRAM)
HK (1) HK1055059A2 (OSRAM)
MX (1) MXPA05003801A (OSRAM)
TW (1) TW200413384A (OSRAM)
WO (1) WO2004033461A1 (OSRAM)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6566372B1 (en) 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
US7026484B2 (en) * 2001-02-23 2006-04-11 Ligand Pharmaceuticals Incorporated Tricyclic androgen receptor modulator compounds and methods
DE20301728U1 (de) 2002-10-11 2004-03-11 Ligand Pharmaceuticals, Inc., San Diego 5-substituierte 7,9-Difluor-5H-Chromeno(3,4-f) -Chinolin-Verbindungen als selektive Progesteronrezeptormodulator-Verbindungen
EP1551845A1 (en) 2002-10-11 2005-07-13 Ligand Pharmaceuticals, Inc. 5-CYCLOALKENYL 5 i H /i -CHROMENO 3,4-F QUINOLINE DERIV ATIVES AS SELECTIVE PROGESTERONE RECEPTOR MODULATOR COMPOUNDS
AU2003258047A1 (en) 2002-10-11 2004-05-04 Ligand Pharmaceuticals Incorporated 5-(1',1'-CYCLOALKYL/ALKENYL)METHYLIDENE 1,2-DIHYDRO-5H-CHROMENO(3,4-f)QUINOLINES AS SELECTIVE PROGESTERONE RECEPTOR MODULATOR COMPOUNDS
MD3820874T2 (ro) * 2018-07-12 2023-05-31 Lilly Co Eli Degradanți selectivi ai receptorului estrogen

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3635941A (en) * 1969-04-01 1972-01-18 Eastman Kodak Co Disperse mono azo dyes containing an acylamidotetrahydroquinoline group
US3907507A (en) * 1971-04-26 1975-09-23 Heliodoro Monroy Rivera Novel apparatus for the obtention of substituted 1,2-dihydroquinolines
CA2074933C (en) 1990-11-30 2002-12-03 Masatoshi Chihiro Thiazole derivatives as active superoxide radical inhibitors
JPH04316557A (ja) 1991-04-16 1992-11-06 Kyorin Pharmaceut Co Ltd ６−アリール環状アントラニル酸誘導体
US5506102A (en) * 1993-10-28 1996-04-09 Ligand Pharmaceuticals Incorporated Methods of using the A form of the progesterone receptor to screen for antagonists of steroid intracellar receptor-mediated transcription
US5696130A (en) * 1994-12-22 1997-12-09 Ligand Pharmaceuticals Incorporated Tricyclic steroid receptor modulator compounds and methods
WO1996019458A2 (en) 1994-12-22 1996-06-27 Ligand Pharmaceuticals Incorporated Steroid receptor modulator compounds and methods
US6696459B1 (en) * 1994-12-22 2004-02-24 Ligand Pharmaceuticals Inc. Steroid receptor modulator compounds and methods
AU728178B2 (en) 1996-06-27 2001-01-04 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
SK284689B6 (sk) * 1998-02-13 2005-09-08 Abbott Laboratories Benzopyrano[3,4-f]chinolínová zlúčenina a liečivo s jej obsahom
US6506766B1 (en) * 1998-02-13 2003-01-14 Abbott Laboratories Glucocortiocoid-selective antinflammatory agents
US6380207B2 (en) 1998-02-13 2002-04-30 Abbott Laboratories Glucocortiocoid-selective antiinflammatory agents
US6093826A (en) * 1998-06-08 2000-07-25 Ligand Pharmaceuticals Incorporated Process for the preparation of C(5)-substituted 1,2-dihydro-5H-chromeno[3,4-f] quinolines
DE20301728U1 (de) 2002-10-11 2004-03-11 Ligand Pharmaceuticals, Inc., San Diego 5-substituierte 7,9-Difluor-5H-Chromeno(3,4-f) -Chinolin-Verbindungen als selektive Progesteronrezeptormodulator-Verbindungen
EP1551845A1 (en) * 2002-10-11 2005-07-13 Ligand Pharmaceuticals, Inc. 5-CYCLOALKENYL 5 i H /i -CHROMENO 3,4-F QUINOLINE DERIV ATIVES AS SELECTIVE PROGESTERONE RECEPTOR MODULATOR COMPOUNDS
AU2003258047A1 (en) * 2002-10-11 2004-05-04 Ligand Pharmaceuticals Incorporated 5-(1',1'-CYCLOALKYL/ALKENYL)METHYLIDENE 1,2-DIHYDRO-5H-CHROMENO(3,4-f)QUINOLINES AS SELECTIVE PROGESTERONE RECEPTOR MODULATOR COMPOUNDS

Also Published As

Publication number Publication date
JP2006504737A (ja) 2006-02-09
AR040781A1 (es) 2005-04-20
CA2501834A1 (en) 2004-04-22
EP1554283A1 (en) 2005-07-20
TW200413384A (en) 2004-08-01
US7163946B2 (en) 2007-01-16
CL2003001545A1 (es) 2005-01-07
MXPA05003801A (es) 2005-06-08
US20040152717A1 (en) 2004-08-05
AU2003258051A1 (en) 2004-05-04
WO2004033461A1 (en) 2004-04-22
DE20301728U1 (de) 2004-03-11

Similar Documents

Publication Publication Date Title
WO2002008186A3 (en) Cyclopentanoindoles, compositions containing such compounds and methods of treatment
AU2002326072A1 (en) Fluoro and sulphonylamino containing 3,6-disubstituted azabicyclo (3.1.0) hexane derivatives as muscarinic receptor antagonists
EP1535613A3 (en) Polymorphic form of atorvastatin calcium
EP0911321A3 (en) Compounds for the treatment of osteoporosis
WO2006034039A3 (en) Substituted morphinans and methods of their use
PL367814A1 (en) 4,5-dihydro-1h-pyrazole derivatives having potent cb1-antagonistic activity
WO2004080377A3 (en) Kcnq channel modulating compounds and their pharmaceutical use
MXPA04002583A (es) Derivados de 4,5-dihidro-1h-pirazol novedosos que tienen actividad antagonistica del canabinoide (cb1).
WO2005000820A3 (fr) Derives de 4-cyanopyrazole-3-carboxamide, leur preparation et leur application comme antagonistes des recepteurs aux cannabinoides cb1
WO2005030188A3 (en) Phenyl-piperazine derivatives as modulators of muscarinic receptors
HK1048632A1 (zh) 雜環取代的吡唑啉酮化合物
AU2002220715A1 (en) Indolsulfonyl compounds useful in the treatment of cns disorders
CA2412208A1 (en) Use of 3-substituted oxindole derivatives as kcnq potassium channel modulators
WO2003082857A3 (en) Lansoprazole polymorphs and processes for preparation thereof
WO2005018573A3 (en) 6-cycloamino-2-quinolinone derivatives as androgen receptor modulator compounds
WO2006058294A3 (en) Modulators of muscarinic receptors
WO2006023852A3 (en) Modulators of muscarinic receptors
WO2004106322A3 (en) Polymorphs of aripiprazole
WO2002030870A3 (de) Substituierte c-cyclohexylmethylamin-derivate
WO2006069276A3 (en) TRICYCLIC ō-OPIOID MODULATORS
WO2003057149A3 (en) 4-substituted fused heteropyrimidines and fused hetero-4-pyrimidones
WO2003037863A3 (de) Substituierte indole, verfahren zu deren herstellung und deren verwendung zur schmerzbekämpfung
WO2003087062A3 (en) 4-(heterocyclyl)-benzenesulfoximine compounds for the treatment of inflammation
EP0980864A3 (en) Sulphonamide derivatives
HK1055058A2 (en) 5-CYCLOALKENYL 5H-CHROMENO[3,4-f]QUINOLINE DERIVATIVES AS SELECTIVE PROGESTERONE RECEPTOR MODULATOR COMPOUNDS

Legal Events

Date Code Title Description
PF Patent in force
PF2 Short-term patent ceased to have effect under s.126(2) (not payment of maintenance fee and has 6-month grace period to pay)

Effective date: 20070804